Abstract

Objective: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease, and uveitis is its most frequent extra-articular complication. Despite advances in management, uveitis remains a major cause of morbidity.

The aim of this study was to evaluate the demographic, clinical, laboratory, and treatment characteristics of patients with JIA-associated uveitis (JIA-U), with a focus on the impact of biologic therapies and potential risk factors for ocular complications.

Material and Methods: This single-center retrospective cohort study included 49 JIA-U patients followed among 550 JIA cases at Ankara Etlik City Hospital (October 2022–November 2023). Demographics, laboratory parameters, clinical features, and treatment outcomes were collected. Patient characteristics were compared according to biologic therapy use and presence of ocular complications.

Results: The prevalence of uveitis was 8.9%. The mean age was 12.8±4.5 years; 61.2% were female. Oligoarticular JIA was the most frequent subtype (57.1%). Uveitis was asymptomatic in 81.6% of patients, and ocular complications occurred in 34.6%. All patients received methotrexate; 67% required biologic therapy, with adalimumab as the first-line agent. At last follow-up, 84% were in remission, 8% had active disease, and 8% were in drug-free remission. No significant differences were found between groups with or without biologic therapy or ocular complications.

Conclusion: Biologic therapies, particularly adalimumab, are effective in managing JIA-U, but their benefits may not be universal. Early diagnosis, regular ophthalmologic screening, and close collaboration between pediatric rheumatologists and ophthalmologists remain essential to reduce complications and improve outcomes.

References

  1. Giancane G, Consolaro A, Lanni S, Davì S, Schiappapietra B, Ravelli A. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatol Ther. 2016;3(2):187-207. https://doi.org/10.1007/s40744-016-0040-4
  2. Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135. https://doi.org/10.1186/s12969-021-00629-8
  3. Kump LI, Cervantes-Castañeda RA, Androudi SN, Foster CS. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology. 2005;112(7):1287-92. https://doi.org/10.1016/j.ophtha.2005.01.044
  4. Päivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78(1):84-8. https://doi.org/10.1034/j.1600-0420.2000.078001084.x
  5. Shin Y, Kang JM, Lee J, Lee CS, Lee SC, Ahn JG. Epidemiology of pediatric uveitis and associated systemic diseases. Pediatr Rheumatol Online J. 2021;19(1):48. https://doi.org/10.1186/s12969-021-00516-2
  6. Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Garcia CA, Becker ML et al. 2018 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol 2019; 71(6): 864-77. https://doi.org/10.1002/art.40885
  7. Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum 2019; 49(1):43-55 https://doi.org/10.1016/j.semarthrit.2018.11.004
  8. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors,and outcome of uveitis in juvenile idiopathic arthritis:a longterm follow-up study. Arthritis Rheum. 2007;56(2):647-57. https://doi.org/10.1002/art.22381
  9. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007; 91(3):319-24 https://doi.org/10.1136/bjo.2006.103721
  10. Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008; 47:339-44 https://doi.org/10.1093/rheumatology/kem356
  11. Foeldvari I, Maccora I, Petrushkin H, Rahman N, Anton J, de Boer J, Calzada-Hernández J, et al. New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2023;75(5):975-82 https://doi.org/10.1002/acr.24963
  12. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. https://doi.org/10.1016/j.clim.2019.108322
  13. Leal I, Miranda V, Fonseca C, Barbosa-Breda J, Cordeiro Sousa D, Mesquita-Marques P et al. The 2021 Portuguese Society of Ophthalmology joint guidelines with Paediatric Rheumatology on the screening, monitoring and medical treatment of juvenile idiopathic arthritis-associated uveitis. ARP Rheumatology (2022);1:49-62
  14. Sahin S, Acari C, Sonmez HE, Kilic FZ, Sag E, Dundar HA, et al. Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER. Pediatr Rheumatol Online (2021);19:134. https://doi.org/10.1186/s12969-021-00613-2
  15. Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12(6):539-45. https://doi.org/10.1016/j.jaapos.2008.03.007
  16. Nordal E, Rypdal V, Christoffersen T, Aalto K, Berntson L, Fasth A et al. Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study. Pediatr Rheumatol Online J. 2017;15(1):66. https://doi.org/10.1186/s12969-017-0195-8
  17. Yasumura J, Yashiro M, Okamoto N, Shabana K, Umebayashi H, Iwata N et al. Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ). Pediatr Rheumatol Online J. 2019;17(1):15. https://doi.org/10.1186/s12969-019-0318-5
  18. Osswald D, Rameau AC, Terzic J, Sordet C, Bourcier T, Sauer A. Risk Factors Leading to Anti-TNF Alpha Therapies in Pediatric Severe Uveitis. Front Pediatr. 2022;10:802977. https://doi.org/10.3389/fped.2022.802977
  19. Horton S, Jones A, Guly C, Hardwick B, Beresford M, Lee R et al. Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial, American Journal of Ophthalmology 2019;207:170-4. https://doi.org/10.1016/j.ajo.2019.06.007nic Anterior Uveitis. Arthritis Care Res (Hoboken). 2023;75(5):975-82.
  20. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 2003;135(5):676-80 https://doi.org/10.1016/S0002-9394(02)02148-7

Copyright and license

Copyright © 2025 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Alkaya A, Özdamar Erol Y, Arslanoğlu Aydın E, Bağlan E, Özdel S. Biologic therapy in juvenile idiopathic arthritis-associated uveitis: Does it make a difference?. Turk J Pediatr Dis. 2025;Early View:1-5. https://doi.org/10.12956/TJPD.2025.1150